Comparing Impact of Overactive Bladder Therapies on Nocturia
- 7 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 30 (3) , 264-271
Abstract
Importance: Nocturia is a significant symptom in overactive bladder with little data regarding the impact of overactive bladder treatments on nocturia. Objectives: Compare the effect of anticholinergic (AC) medication, onabotulinum toxin A (BTX), and sacral neuromodulation (SNM) on nocturia. Study Design: Secondary analysis of the ABC and ROSETTA trials using data from the National Institutes of Health Data and Specimen Hub database. Patients reporting mean ≥2 voids/night on 3-day diary were included and divided into cohorts by treatment: the ABC trial: (1) AC and (2) BTX 100 units, and the ROSETTA trial: (3) BTX 200 units and (4) SNM. Primary outcome was change in mean voids/night on 3-day diary from baseline to 6 months assessed by mixed-effects models for repeated-measures data with interaction between treatment cohort and time included in model. Results: A total of 197 patients were included: 43 (22%) AC, 37 (19%) BTX 100 U, 63 (32%) BTX 200 U, and 54 (27%) SNM. There were no significant differences in baseline voids/night, demographics, or urodynamic values except for younger age in AC and BTX 100 U cohorts (P = 0.04). At 6 months, all cohorts demonstrated a mean 41% decrease in mean voids/night (2.7 ± 0.4 at baseline to 1.6 ± 0.5 at 6 months; P < 0.001), with no significant difference in change in mean voids/night between treatment cohorts (decrease of 44% in AC, 46% in 100 U BTX, 32% 200 in U BTX, and 33% in SNM; P > 0.05). Conclusion: For women with nocturia ≥2/night, treatment with AC, BTX 100 or 200 units, or SNM led to a significant decrease in voids/night at 6 months.Keywords
This publication has 17 references indexed in Scilit:
- What Is the Most Effective Treatment for Nocturia or Nocturnal Incontinence in Adult Women?European Urology Focus, 2021
- Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysisWorld Journal of Urology, 2018
- OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in WomenJAMA, 2016
- Can botox improve night‐time overactive bladder symptoms in women?Neurourology and Urodynamics, 2016
- The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trialContemporary Clinical Trials, 2014
- An overactive bladder symptom and health-related quality of life short-form: Validation of the OAB-q SFNeurourology and Urodynamics, 2014
- OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2013
- Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analysesEuropean Urology, 2012
- Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trialContemporary Clinical Trials, 2012
- Prevalence and burden of overactive bladder in the United StatesWorld Journal of Urology, 2003